Search Results - "Skedgel, C."

The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use by Dhatariya, K. K., Skedgel, C., Fordham, R.

“…Aim Diabetic ketoacidosis is a commonly encountered metabolic emergency. In 2014, a national survey was conducted looking at the management of diabetic…”
Get full text

The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison by Skedgel, C

“…The pan-Canadian Oncology Drug Review (pcodr) is responsible for making coverage recommendations to provincial and territorial drug plans about cancer drugs…”
Get full text

Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review by Younis, T., Rayson, D., Jovanovic, S., Skedgel, C.

“…The adoption of primary (PP) versus secondary prophylaxis (SP) of febrile neutropenia (FN), with granulocyte colony-stimulating factors (G-CSF), for adjuvant…”
Get full text

Identification of patients with systemic lupus erythematosus in administrative healthcare databases by Hanly, J G, Thompson, K, Skedgel, C

“…Objective Our aim was to validate and compare decision rules for the identification of patients with systemic lupus erythematosus (SLE) in administrative…”
Get full text

The cost of treating diabetic ketoacidosis in an adolescent population in the UK: a national survey of hospital resource use by Dhatariya, K. K., Parsekar, K., Skedgel, C., Datta, V., Hill, P., Fordham, R.

“…Aims Adolescents with Type 1 diabetes commonly experience episodes of ketoacidosis. In 2014, we conducted a nationwide survey on the management of diabetic…”
Get full text

Timeliness of the oncology drug review process for public funding in Canada by Younis, T, Skedgel, C

“…The oncology drug review process for public funding in Canada (Figure 1) encompasses both. [...]…”
Get full text

Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer? by Skedgel, C., Rayson, D., Younis, T.

“…In light of clinical uncertainty and the high acquisition costs of trastuzumab, we examined the value for money associated with concurrent or sequential…”
Get full text

The politicization of oncology drug funding reviews in Canada by Skedgel, C, Younis, T

“…An article in this issue by Srikanthan, [...]…”
Get full text

Evidence in medicine: math versus biology by Younis, T, Thana, M, Skedgel, C

“…The drive for optimal clinical decisions based on "best" evidence has gained significant momentum in the last few decades. [...]…”
Get full text

The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer by Younis, T, Rayson, D, Skedgel, C

“…The adoption of a chemotherapeutic regimen in oncologic practice is a function of both its clinical and its economic impacts on cancer management. For breast…”
Get full text

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? by BROWN, M. G, KIRBY, S, SKEDGEL, C, FISK, J. D, MURRAY, T. J, BHAN, V, SKETRIS, I. S

“…Our objective was to estimate the effectiveness of disease-modifying drugs (DMDs) in delaying multiple sclerosis (MS) disability progression in relapsing-onset…”
Get full text

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women : sequential tamoxifen-exemestane and upfront anastrozole by SKEDGEL, C, RAYSON, D, DEWAR, R, YOUNIS, T

“…Adjuvant Anastrozole (ANA) for 5 years and Tamoxifen followed by Exemestane (TAM-EXE) for 2.5 years each have become acceptable alternatives to 5 years of…”
Get full text

Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels by Lamond, N W D, Skedgel, C, Rayson, D, Younis, T

“…Adjuvant zoledronic acid (za) appears to improve disease-free survival (dfs) in women with early-stage breast cancer and low levels of estrogen (lle) because…”
Get full text

Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer by Younis, T., Rayson, D., Dewar, R., Skedgel, C.

“…Background: To determine cost-effective (CE) strategies comparing adjuvant upfront aromatase inhibitor (AI) with sequential tamoxifen (TAM) AI in…”
Get full text

Cost‐utility analysis of proton pump inhibitors and other gastro‐protective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal anti‐inflammatory agents by CAMERON, C., VAN ZANTEN, S. V., SKEDGEL, C., FLOWERDEW, G., MOAYYEDI, P., SKETRIS, I.

“…Aliment Pharmacol Ther 31, 1354–1364 Summary Background  The use of proton pump inhibitors (PPIs) among elderly patients using nonselective nonsteroidal…”
Get full text

Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: Upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole by Skedgel, C, Rayson, D, Dewar, R, Younis, T

“…Summary This evaluation adapts a previous Canadian analysis of upfront and sequential adjuvant AI strategies in postmenopausal women with breast cancer to a…”
Get full text

The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada by Drucker, A, Skedgel, C, Virik, K, Rayson, D, Sellon, M, Younis, T

“…Monoclonal antibodies (MAbs) such as trastuzumab and bevacizumab have become important yet expensive components of systemic cancer therapy across a variety of…”
Get full text

SP4 A Longer Life or a Quality Death? a Discrete Choice Experiment to Estimate the Relative Importance of Different Aspects of END-of-Life Care by Skedgel, C., Robinson, A.

Get full text

How effective are disease-modifying drugs in delaying progression in relapsing-onset ms? by Brenner, Steven R, Brown, M G, Kirby, S, Skedgel, C, Fisk, J D, Murray, T J, Bhan, V, Sketris, I S

Get full text

EE664 The Basis for a New Framework to Determine the Cost-Effectiveness Threshold by Berdud, M, Sampson, C, Kourouklis, D, Skedgel, C

Get full text